ClinicalTrials.Veeva

Menu

Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia

O

Olive Lifesciences

Status

Unknown

Conditions

Hyperlipidemia
Chronic Smokers

Treatments

Dietary Supplement: BioTurmin-WD (Water dispersible curcuminoids)
Dietary Supplement: BioTurmin (Curcuma longa rhizomes extract)
Other: Placebo
Dietary Supplement: MaQxan (Tagetes erecta flower extract)

Study type

Interventional

Funder types

Industry

Identifiers

NCT02100202
OLS-SH/02-14 Ver 01

Details and patient eligibility

About

The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate hyperlipidemia after 30 days of intervention.

Full description

In a randomized, double-blind, placebo control trial, the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) will be investigated in chronic smokers having mild to moderate hyperlipidemia. Sixty subjects will be randomly assigned to receive the dietary supplements and placebo for 30 days. The efficacy of the supplements will be measured by estimating cotinine and malondialdehyde level.

Enrollment

60 estimated patients

Sex

Male

Ages

20 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Men > 20 years

Chronic cigarette/ beedi smoker (2-3 packets/day since last 3 years or more) with mild to moderate hyperlipidemia (LDL ranging 160-189 mg/dL, TC >200 mg/dL and/or HDL-C <40 mg/dL)

Being mentally competent and able to understand all study requirements and sign the informed consent form.

Exclusion criteria

Patients with Chronic obstructive pulmonary disease (COPD)

Women

Patients with severe liver, renal, cardiac or brain diseases.

Unable to complete follow up.

Subjects on any medication like diuretics.

Allergic to any medication.

With a history of alcohol and/or drug abuse.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

60 participants in 4 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Capsules containing 250 mg of placebo, two times a day
Treatment:
Other: Placebo
BioTurmin
Experimental group
Description:
Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
Treatment:
Dietary Supplement: BioTurmin (Curcuma longa rhizomes extract)
BioTurmin-WD
Experimental group
Description:
Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
Treatment:
Dietary Supplement: BioTurmin-WD (Water dispersible curcuminoids)
MaQxan
Experimental group
Description:
Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
Treatment:
Dietary Supplement: MaQxan (Tagetes erecta flower extract)

Trial contacts and locations

1

Loading...

Central trial contact

Bhanumathy M, M Pharma; Shivaprasad H N, M Pharma, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems